All University Medicine Greifswald articles
-
NewsInnovative phage lysin HY-133 enters phase I clinical study
HYpharm’s innovative preventive agent HY-133 has reached the first clinical trial phase. HY-133 is specifically effective against Staphylococcus aureus including multi-resistant strains and is intended to combat its colonisation in the nose.
